✦ LIBER ✦

PCN41 COST-EFFECTIVENESS OF TAC VERSUS FAC FOR THE TREATMENT OF NODE POSITIVE BREAST CANCER IN THE ADJUVANT SETTING

✍ Scribed by M Fonseca; G Araujo; E Saad; R Uehara

Book ID: 119594367
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 72 KB
Volume: 9
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)63471-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost–effectiveness analysis of adjuvant

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ Sang Gyu Lee; Young Geon Jee; Hyun Chul Chung; Sung-Bae Kim; Jungsil Ro; Young-H 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 231 KB

PCN8 COST-EFFECTIVENESS OF ANASTROZOLE V

PCN8 COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN FOR THE TREATMENT OF POST MENOPAUSAL HORMONE-RECEPTOR POSITIVE BREAST CANCER (BC) IN THE ADJUVANT SETTING IN BRAZIL

✍ M Fonseca; G Araujo; E Saad 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJ

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING

✍ H AlOmar; AS Zazaa; M AlFayyadh; JA Ray 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Cost-effectiveness analysis of adjuvant

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

✍ Heather-Jane Au; Kamran Golmohammadi; Tallal Younis; Shailendra Verma; Stephen C 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 307 KB

P180 A cost effectiveness analysis of ad

P180 A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ B.L. Rapoport; S.D. Moodley; C. Jacobs; R. Pienaar; S. Fourie; W.M. Szpak 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 44 KB